5 biopharmaceutical stocks to watch amid global economic growth concerns


Are these most important biopharmaceutical stocks on your September 2021 watchlist?

As stocks continue to sell in September, biopharmaceutical actions continue to gain ground in the stock market today. In addition to investor fears over large-scale sales, new economic data from China is also weighing on the market. stock Exchange now. Namely, China’s retail sales, industrial production, and growth in capital investment all slowed down significantly in August. This would to some extent affect the overall outlook for the current global economic recovery. In addition, there is also the factor of the more infectious Delta variant of the coronavirus persisting across the world.

For the most part, all of these factors could highlight the biopharmaceutical industry now. As concerns grow about reopening world trade, investors would look to more defensive actions. Among them, biopharmacy giants such as AstraZeneca (NASDAQ: AZN) and Sanofi (NASDAQ: SNY). Notably, the two companies are also working hard to expand their operations now. On the one hand, AstraZeneca is now focused on supporting general healthcare research in Saudi Arabia. Sanofi also finalized the acquisition of Translate Bio, a biotechnology company specializing in mRNA gene therapy. With all this activity in the biopharmaceutical space now, here are 5 biopharmaceutical actions to watch this week.

The best biopharmaceutical stocks to watch right now

Adagio Therapeutics Inc.

Therapeutic Adagio is a clinical-stage biopharmaceutical company that develops and markets antibody-based solutions for infectious diseases with pandemic potential. Its main product candidate includes ADG20, which is designed to be a potent, long-acting, broadly neutralizing antibody for the treatment and prevention of the virus.

Last week, he announced that the Independent Data Monitoring Committee (IDMC) for the phase 2/3 trial of EVADE of ADG20 had made a recommendation to expand the recruitment of phase 3 trials of ADG20. company. Given the urgent need for additional treatments and preventive options for the pandemic, the company hopes that this inclusion of adolescents and pregnant or breastfeeding women in the next phase of the study will help pave the way for more. of people with access to treatment.

In addition, the company claims that this antibody treatment has the potential to become the preferred prophylactic option for the virus as these groups are currently limited or have no options available. That being said, is ADGI stock worth watching right now?

Source: TD Ameritrade CGU

Read more

Pfizer Inc.

then, we have Pfizer, a multinational pharmaceutical company headquartered in New York City. The company’s portfolio of treatments and drugs have impacted the lives of millions of people around the world and dramatically improved the quality of life. With over 170 years in the industry, the company is certainly a biopharmaceutical titan. Recently, he announced the FDA’s acceptance of a review of a new supplemental drug application for Myfembree. Myfembree is used for the management of moderate to severe pain associated with endometriosis.

Last month, the company also announced that it had entered into a definitive agreement to acquire Trillium, a clinical-stage immuno-oncology company that develops innovative therapies to treat cancer. In addition, under the terms of the agreement, Pfizer will acquire all of the outstanding shares of Trillium for an implied value of $ 2.26 billion or $ 18.50 per share in cash.

The acquisition of Trillium will build on Pfizer’s strong track record in oncology. It will also enhance its hematology portfolio as the company strives to improve outcomes for people living with blood cancers around the world. For these reasons, will you consider investing in PFE stocks?

Top biopharmaceutical stocks (PFE stock)Source: TD Ameritrade CGU

[Read More] The best stocks to buy now? 4 renewable energy actions for your watchlist

Vera Therapeutics Inc.

Vera Therapeutics is a clinical-stage biotechnology company developing transformative treatments for patients with severe immunological diseases. For example, its main program is atacicept, a fusion protein that is under development for IgA nephropathy, a disease with high unmet medical needs and no approved therapy. VERA stock has risen by over 140% in the past year alone.

On August 16, 2021, the company released its second quarter financial results and provided a business update. Vera Therapy said she achieved key clinical and financial milestones in the first half of the year.

Marshall Fordyuce, Founder and CEO of Vera Therapeutics said: “In the second quarter, we launched our Phase 2b clinical trial of atacicept in patients with IgA nephropathy (IgAN) as planned. Known as “ORIGIN”, this trial will potentially demonstrate atacicept as the first disease-modifying treatment for patients with IgAN. ORIGIN is a randomized controlled trial to determine whether the proven ability of atacicept to significantly reduce Gd-IgA1 results in improvements in kidney function, as measured by proteinuria. We look forward to providing additional clinical updates scheduled for the remainder of 2021 through 2022.That being said, will you consider adding VERA stocks to your portfolio now?

VERA stock chartSource: TD Ameritrade CGU

Eli Lilly and company

Another name to consider in the biopharmaceutical industry today would be Eli Lilly and company (THERE IS). In short, LLY is a pharmaceutical goliath with operations across the world. For a sense of scale, the company has offices in 18 countries while its products are strong in around 125 countries. The company’s portfolio currently consists of treatments for a wide range of diseases. This includes, but is not limited to diabetes, cancer, diseases related to the endocrine system, and COVID-19.

Today, LLY’s stock is up over 40% since the start of the year. On top of all this, LLY seems eager to maintain her current momentum. Earlier today, the company revealed it will provide an additional 388,000 doses of its COVID-19 treatment, etesevimab, to the US government. After considering all of this, will you add LLY stock to your watchlist?

best biopharmaceutical stocks (LLY stock)Source: TD Ameritrade CGU

AbbVie Inc.

AbbVie is a biopharmaceutical company that develops cutting-edge drugs with strong clinical performance in areas where needs are great. Its main therapeutic areas include immunology, oncology, neuroscience, virology and eye care. ABBV shares have risen by over 18% over the past year. On Monday, the company announced a partnership with Regenxbio (NASDAQ: RGNX) for collaboration in eye care.

In detail, the two companies will develop and market RGX-314, a unique potential gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. Regenxbio will complete its ongoing trials while Abbvie will share the costs of additional RGX-314 trials. By leveraging AbbVie’s global eye care development and business infrastructure, this collaboration could prove fruitful for the company in the years to come. Are you planning to keep an eye on ABBV’s stock with this news?

ABBV stock chartSource: TD Ameritrade CGU

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.